Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

'_blank' title='http://www.CellTherapeutics.com/investors_alert'>http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, the potential failure of pixantrone to significantly reduce cardiac cell toxicity compared to currently marketed anthracyclines, the potential failure of pixantrone to reintroduce an effective anthracycline like agent in patients, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  EnteroMedics Inc. (NASDAQ: ... technology to treat obesity, metabolic diseases and other gastrointestinal ... call on Thursday, August 7, 2014 at 11:00 AM ... quarter ended June 30, 2014 and to provide a ... The second quarter conference call may be accessed by ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
(Date:7/29/2014)... , July 29, 2014  Synthetic Biologics, Inc. ... and drug candidates targeting specific pathogens that cause serious ... the unusual market activity in the Company,s stock, the ... accordance with its usual practice. The Company stated that ... activity. About Synthetic Biologics, Inc. ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... New soluble polymer material,designed to stop bone bleeding ... new animal study just published in the Annals of ... recently published,research showing that the use of the new ... from the Medical University of South Carolina at Charleston,and ...
... AG (,Intercell,) to acquire Iomai Corporation (,Iomai,) in ... per share of Iomai,s common stock ... of approximately USD 189 million (EUR ... exchange for approximately 41 percent of Iomai,s ...
Cached Medicine Technology:Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 2Ceremed's OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 2Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 3Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 4Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 5Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 6Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 7Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 8Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 9Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 10Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation 11
(Date:7/30/2014)... HealthDay Reporter , TUESDAY, July 29, 2014 (HealthDay ... stage for harmful health habits, including eating disorders, according to ... to 2012 also found a link between early dieting and ... was when she started her first diet, the more likely ... like vomiting or laxative misuse," said study researcher Lauren Holland, ...
(Date:7/30/2014)... Researchers from the University of So Paulo (USP) have ... no instructions for the production of a protein, modulates ... of apoptosis, or programmed cell death. , According ... and coordinator of a research funded by So Paulo ... cancer cells, and methods that are capable of stimulating ...
(Date:7/30/2014)... We know pregnancy cravings don’t always inspire the ... cream—but the latest episode of the Telly Award-winning web series ... has a recipe that is delicious, satisfying and, most of ... serves up an easy recipe that supports a healthy diet ... Rasika, which was named one of the 20 top-rated restaurants ...
(Date:7/30/2014)... Chinese researchers say a protein that makes up ... used as a prognostic indicator in people on chemotherapy for ... article on the study , just posted on the Surviving ... Medicine at Shandong University Hospital in China analyzed the albumin ... 1995 and 2013. They found that, the lower the albumin ...
(Date:7/30/2014)... Seattle, Wa (PRWEB) July 30, 2014 It is ... as they would want to be in life is because they ... However, as recent research shows, this belief is only an ... they can achieve more had they been only “smarter”. , So, ... but also by one’s willingness to work hard for that success. ...
Breaking Medicine News(10 mins):Health News:Dieting at Young Age Often Backfires, Study Says 2Health News:Dieting at Young Age Often Backfires, Study Says 3Health News:Brazilian researchers identify RNA that regulates cell death 2Health News:Brazilian researchers identify RNA that regulates cell death 3Health News:What to Eat When You’re Expecting 2Health News:Study Finds Common Blood Protein May Predict Mesothelioma Survival, Reports Surviving Mesothelioma 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 2Health News:Brain Evolution System - #1 Brainwave Entrainment Meditation Program Review | Unleashing One’s Ultimate Potential Improving Mind Power – Vinamy 3
... Bavarian Nordic,reports the successful completion of a ... who received either one or two doses of,IMVAMUNE(R) ... are seen as the pivotal step on the ... in order to achieve a BLA for healthy,subjects., ...
... CHICAGO, Nov. 29 , What: Join Zoraida Sambolin, co-anchor of the ... and Easter Seals at the 2007 Easter Seals Metropolitan ... event that benefits local Chicago programs ... with autism, including the new Therapeutic School and Center ...
... to lamotrigine use, research shows , THURSDAY, Nov. 29 ... drug lamotrigine in pregnant women with epilepsy can help reduce ... Lamotrigine, an epilepsy drug, is taken by pregnant women with ... defects. However, the drug has also been linked to increased ...
... this to a human ,fountain of youth, however , , THURSDAY, ... able to temporarily return old skin cells to their youthful ... "This gene gets more and more active with age," said ... at Stanford University. "It doesn,t exist to make us ...
... report the discovery of biological markers of prostate cancer ... shedding light on the genetic basis for the prostate ... is being presented today at the American Association for ... Disparities in Racial/Ethnic Minorities and the Medically Underserved, being ...
... A study led by a University of Pennsylvania biologist in ... widely held belief that mice are the main animal reservoir ... published in the Proceedings of the Royal Society B, demonstrates ... the four species that account for major outbreaks. , According to ...
Cached Medicine News:Health News:Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate 2Health News:Easter Seals Festival of Trees Holiday Gala Will Make a Difference for Children and Adults With Autism 2Health News:Tracking Drug Levels Helps Pregnant Women With Epilepsy 2Health News:Gene Tweak Reverses Aging in Mouse Skin Cells 2Health News:Biological markers of prostate cancer shed light on cancer burden faced by African-American men 2Health News:University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: